Wyeth's Xyntha gets FDA OK

02/21/2008 | MarketWatch

The FDA on Thursday announced that it has cleared Wyeth's drug Xyntha as treatment for rare blood-clotting disorder hemophilia A. The drug is indicated for regulating and preventing spontaneous or post-injury bleeding in patients with the disorder.

View Full Article in:

MarketWatch

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Global Medical Safety Director - Transcatheter Heart Valve
Edwards Lifesciences
Irvine, CA
Compliance Manager/Sr. Compliance Manager- Auditing
Genentech
South San Francisco, CA
Director of Program Development
AdvaMed
Washington DC, DC
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC